Severe Menstrual Disorders Linked to Higher Rates of Thyroid Issues and Dyslipidemia

Young women struggling with painful periods or endometriosis face a significantly higher likelihood of also dealing with thyroid disorders and dyslipidemia, according to a nationwide study published in PLOS One. The cross-sectional investigation examined health insurance claims data for more than 3.4 million female patients under the age of 40, revealing that endocrine and metabolic conditions frequently overlap with common menstrual-related complaints.

Why Menstrual Disorders Go Beyond Pelvic Health

For decades, medical professionals viewed conditions like endometriosis and severe menstrual cramps as localized issues confined strictly to the pelvic region. However, a growing body of clinical research points to systemic inflammation, immune dysregulation, and metabolic shifts as key players in these disorders. To better understand how widespread these secondary health issues might be, a research team led by scientists at the University of Yamanashi analyzed medical records from the Japan Medical Data Center Claims Database for the year 2023.

The study population captured 257,897 women diagnosed with menstrual-related disorders, which included confirmed cases of endometriosis, dysmenorrhea, or both. Their health data were compared against a control group of 3,183,032 women without recorded menstrual diagnoses. The primary outcomes tracked the frequency of various thyroid-related diagnoses, such as hypothyroidism and hyperthyroidism, alongside dyslipidemia, which refers to unhealthy levels of lipids or fats like cholesterol in the blood.

The Striking Numbers Behind Thyroid Conditions and Dyslipidemia

The findings indicate that thyroid issues and lipid imbalances appear far more frequently in women with painful or irregular menstrual conditions than in their peers. Hypothyroidism, a condition where the thyroid gland fails to produce enough hormones to meet the body’s needs, turned up in 2.1 percent of women within the menstrual-related disorders group, compared to just 0.8 percent of controls. When looking specifically at the endometriosis subgroup, that prevalence climbed to 2.6 percent.

Hyperthyroidism, characterized by an overactive thyroid gland producing excessive hormones, was identified in 1.6 percent of the menstrual disorder cohort and 2.0 percent of the endometriosis subgroup, against 0.7 percent of the control group. Other conditions, including non-toxic goiter and thyroiditis, followed the same elevated pattern. Meanwhile, dyslipidemia showed an even larger gap, appearing in 5.2 percent of the menstrual disorder group and 6.1 percent of the endometriosis subgroup, compared to a baseline of 1.4 percent among controls.

What These Associations Mean for Younger Patients

Even after adjusting the data for age differences using the Mantel-Haenszel method, the statistical associations remained robust, with adjusted prevalence ratios ranging from 1.45 to 3.02 across various comparisons. Interestingly, women suffering from dysmenorrhea alone also displayed elevated rates of these endocrine and metabolic comorbidities, suggesting that menstrual pain may serve as an early clinical warning sign for broader systemic vulnerability rather than a simple localized inconvenience.

The authors also evaluated whether common hormonal treatments, such as low-dose estrogen-progestin preparations or dienogest, altered these patterns. Among women with menstrual disorders, hypothyroidism was actually less frequent in those actively receiving these prescriptions compared to those without them. However, the researchers emphasize that this difference likely stems from clinical prescribing habits rather than a direct protective pharmacological effect, as patients with more complex symptom burdens or specific medical needs may be guided toward alternative treatment paths.

Important Limitations to Keep in Mind

Because the investigation relied entirely on a cross-sectional analysis of administrative claims data, the authors caution that the findings reflect co-recorded diagnoses rather than proven cause-and-effect relationships. The dataset did not track laboratory test results, body mass index, smoking habits, or family history, meaning other underlying lifestyle and genetic factors could not be fully accounted for in a multivariable model.

Additionally, the research team noted the possibility of surveillance bias. Women managing chronic pelvic pain and menstrual disorders tend to visit healthcare providers much more frequently than healthy controls, creating more opportunities for doctors to incidentally diagnose secondary conditions like mild thyroid dysfunction or early lipid abnormalities. Despite these observational limits, the findings underscore the importance for clinicians to look beyond the pelvis and consider wider metabolic and endocrine health when caring for young patients with menstrual complications.

The research was published in PLOS One on October 30, 2026.